The Treatment of Relapsed and Refractory Multiple Myeloma
Open Access
- 1 January 2007
- journal article
- review article
- Published by American Society of Hematology in Hematology
- Vol. 2007 (1), 317-323
- https://doi.org/10.1182/asheducation-2007.1.317
Abstract
Relapsed and refractory multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short. Patients with relapsed/refractory disease are defined as those who, having achieved minor response or better, relapse and then progress while on salvage therapy, or experience progression within 60 days of their last therapy. In the era prior to the development of novel biologically based therapies for MM, relapse from successive treatment regimens resulted in progressively shorter response durations, which typically reflected emerging drug resistance, as well as changes in disease biology within each patient, with tumor cells expressing a more aggressive phenotype, higher proliferative fraction and lower apoptotic rates.Both bortezomid- and lenalidomide-based therapies are expecially active, with bortezomib in particular being shown to provide a platform for combinations able to overcome resistance in this setting. The addition of novel and conventional agents to the treatment backbone of lenalidomide, thalidomide, and bortezomib are areas of active study, with participation in clincial trials a clear priority for such patients. Clinical challenges in the relapsed/refractory population include light chain and IgA isotype, renal failure, extramedullary disease, hyposecretory myeloma, and advanced bone disease.Keywords
This publication has 35 references indexed in Scilit:
- Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myelomaBritish Journal of Haematology, 2007
- Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myelomaBlood, 2006
- Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective studyBlood, 2006
- A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood, 2006
- Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trialsLeukemia, 2006
- Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinationsThrombosis and Haemostasis, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myelomaThe Hematology Journal, 2004
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002